Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

ds. The decrease in both periods is primarily due to lower personnel costs, professional fees, reduced patient, site, lab, data management, monitoring and materials costs related to our TNFerade(TM) program, reduced materials costs related to our funded programs, and reduced general lab materials and supplies.

GenVec ended the third quarter of 2009 with $14.2 million in cash and investments.

"Based on existing contracts and collaborations, we anticipate revenues for 2009 will be between $14.0 million and $16.0 million. We project our cash burn to be between $12.0 million and $14.0 million for the 12 months ending September 30, 2010 although our spending will be heavily influenced by the availability of capital," commented Douglas J. Swirsky, GenVec's Senior Vice President and Chief Financial Officer. "Our primary focus remains on TNFerade and the PACT trial and we look forward to sharing additional data from this pivotal trial next year."

Third Quarter and Recent Highlights

  • GenVec has enrolled 277 patients in the pivotal PACT trial as of October 31, 2009.
  • GenVec's lead product candidate, TNFerade, was granted orphan drug designation by the FDA. Orphan drug designation provides potential financial and regulatory incentives including study design assistance, waiver of FDA user fees, tax credits, and up to seven years of market exclusivity upon marketing approval.
  • GenVec signed a contract with the SAIC for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will receive approximately $2.6 million under the base year of the contract.
  • GenVec was awarded an approximately $2.5 million Small Business Innovation and
    '/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2015 results before the Nasdaq market opens on Thursday, ... call and webcast to discuss its financial results and ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... by dialing 866-952-1906 (US) or 785-424-1825 (International) using the ...
(Date:4/23/2015)... , April 23, 2015  Veracyte, Inc. (NASDAQ: VCYT ... definitive agreement to sell approximately $40 million of its ... the investors will purchase an aggregate of 4,907,975 shares ... per share, the closing stock price on April 22, ... existing investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood ...
(Date:4/23/2015)... , April 23, 2015  Metanome, Inc., an ... the company has changed its name to Diversigen, ... positioning as the single commercial source for the ... capitalize on the diverse opportunities of the microbiome. ... Diversigen accepts – including those that are difficult ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... April 10 Dedicating this year,s,Venture Forum to the ... announced a partnership in developing and producing the 2008,Life ... and,innovative seed and early-stage life sciences companies from the ... Forum will take place on,May 30, 2008, at the ...
... Medicsight PLC, a,subsidiary of MGT Capital Investments, ... in the development of Computer-Aided Detection (CAD) and ... and diagnosis of,disease, today announced that it has ... Administration ("SFDA") for its MedicRead Colon,workstation. Medicsight will ...
... -, PRINCETON, N.J., April 10, 2008 ... production,company, today announced that it has entered into ... According to the,agreement, Laureate will produce Alopexx,s mAb ... for use in clinical trials, and later,for commercial ...
Cached Biology Technology:Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 2Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 3Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 2Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 22, 2011) - An animal,s behavior is probably ... alike. Its behavior involves processes internal to the animalgenetics, ... and social surroundings. According to the book,s authors, "Animal ... is sparked when neurons fire in response to stimuli ...
... available in German . The ... career researchers in Germany have been chosen. The selection ... Foundation) and the German Federal Ministry of Education and ... male researchers for the Heinz Maier-Leibnitz Prize 2011. The ...
... Research Council (BBSRC) announces the signing of a Memorandum of ... and Technology (MOST) in Vietnam. This heralds the start of ... tolerance in the world,s most important staple food in the ... Funds of up to 350K are being made available by ...
Cached Biology News:New book on animal behavior provides integrated view 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 3Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 4Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 5UK-Vietnam collaboration to improve world's most important staple food 2UK-Vietnam collaboration to improve world's most important staple food 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Biology Products: